The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Nov. 29, 2016
Filed:
Sep. 01, 2015
Applicant:
Children's Hospital Medical Center, Cincinnati, OH (US);
Inventors:
Daniel Starczynowski, Cincinnati, OH (US);
Garrett W. Rhyasen, Cincinnati, OH (US);
Assignee:
Children's Hospital Medical Center, Cincinnati, OH (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07H 21/02 (2006.01); C07H 21/04 (2006.01); A61K 48/00 (2006.01); A61K 31/7105 (2006.01); A61K 31/5377 (2006.01); C12N 15/113 (2010.01); A61K 31/4184 (2006.01); A61K 31/495 (2006.01); A61K 31/454 (2006.01); A61K 31/635 (2006.01); A61K 45/06 (2006.01);
U.S. Cl.
CPC ...
A61K 31/7105 (2013.01); A61K 31/4184 (2013.01); A61K 31/454 (2013.01); A61K 31/495 (2013.01); A61K 31/5377 (2013.01); A61K 31/635 (2013.01); A61K 45/06 (2013.01); C12N 15/1137 (2013.01); C12N 2310/11 (2013.01); C12N 2310/531 (2013.01);
Abstract
Disclosed are compositions and methods for the treatment of disorders such as myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). The disclosed methods include administering to an individual in need of such treatment a composition that may include an IRAK1/4 inhibitor. In other aspects, the method may include administration of a BLC2 inhibitor.